南美的胰臟癌治療及診斷市場-成長，趨勢，及預測(2020年∼2025年)

南美的胰臟癌治療及診斷市場成長的主要因素有胰腺癌患病率增加以及對該疾病的診斷和治療需求增加等。結果許多政府和非營利組織都主動提高了南美地區對胰腺癌的認識。

本報告提供南美的胰臟癌治療及診斷市場調查，提供市場概要，市場成長要素及阻礙因素分析，各類型·各地區的市場規模的變化與預測，競爭情形，主要企業的簡介，市場機會等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

• 市場概要
• 市場推動因素
  • 胰臟癌症的發生率和盛行率增加
  • 新產品的技術進步與創新
• 市場阻礙因素
  • 治療和診斷相關的高成本
  • 藥物的毒性和副作用
• 波特的五力分析

第5章 市場區隔

• 各類型
  • 不同治療
  • 各診斷
• 各地區
  • 南美

第6章 競爭情形

• 企業簡介
  • Bristol-Myers Squibb
  • Canon Medical Systems
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Hitachi Medical
  • Novartis AG
  • Pfizer Inc
  • Philips Healthcare
  • Siemens AG

第7章 市場機會及趨勢

The market studied is majorly driven by factors, such as the increasing prevalence of pancreatic cancer and the increasing demand for diagnostic tests and treatments of this disease. As a result, many governments and non-profit organizations have taken initiatives to spread awareness regarding pancreatic cancer in the South American region.

Moreover, the technological advancements in diagnostics and treatments have have led to solutions that are more efficient. Hence, all these are the major factors that have propelled the growth of the market.

Key Market Trends

Chemotherapy Segment is Expected to Cover a Large Share of the Pancreatic Cancer Therapeutics & Diagnostics Market

Chemotherapy is the use of drugs to destroy cancer cells, usually by ending the cancer cells ability to grow and divide. A chemotherapy regimen, or schedule, usually consists of a specific number of cycles given over a set period of time. There is usually a rest period in between cycles. A patient may receive 1 drug at a time or a combination of different drugs given at the same time. Chemotherapy thus is an important part of multimodality pancreatic cancer treatment. After curative resection, adjuvant chemotherapy can significantly improve disease-free survival and overall survival. Therefore this will increase the demand for chemotherapy therapy in future, which is expected to help the market growth.

Competitive Landscape

South America is a developing region. Although the healthcare system in many countries in the region are not highly developed, these countries are spending more each year in their healthcare system. This has encouraged many global companies to enter the market and as a result, many global players in the pancreatic cancer therapeutics and diagnostics market are present in the region. These factors have made the region very competitive.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer
  • 4.2.2 Technological Advancements and Innovation of New Products
• 4.3 Market Restraints
  • 4.3.1 High Costs Associated with Treatment and Diagnosis
  • 4.3.2 Drug Toxicity and Side Effects
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Type
  • 5.1.1 By Treatment
    • 5.1.1.1 Surgery
    • 5.1.1.2 Chemotherapy
    • 5.1.1.3 Targeted Therapy
    • 5.1.1.4 Other Treatments
  • 5.1.2 By Diagnostics
    • 5.1.2.1 Imaging
    • 5.1.2.2 Biopsy
    • 5.1.2.3 Endoscopy
    • 5.1.2.4 Other Diagnostics
• 5.2 Geography
  • 5.2.1 South America
    • 5.2.1.1 Brazil
    • 5.2.1.2 Argentina
    • 5.2.1.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Bristol-Myers Squibb
  • 6.1.2 Canon Medical Systems
  • 6.1.3 Eli Lilly and Company
  • 6.1.4 F. Hoffmann-La Roche AG
  • 6.1.5 GE Healthcare
  • 6.1.6 Hitachi Medical
  • 6.1.7 Novartis AG
  • 6.1.8 Pfizer Inc
  • 6.1.9 Philips Healthcare
  • 6.1.10 Siemens AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS